Company: INDP
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010099
Chunk: 5

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 8
Chunk 5
---
)  
    Intrinsic value 
  
    Outstanding as of January 1, 2025 
     2,887,822  
    $8.06  
     7.6  
    $- 
  
    Granted 
     -  
    $-  
     -  
    $- 
  
    Forfeited and cancelled 
     (625) 
    $-  
     -  
    $- 
  
    Outstanding as of March 31, 2025 
     2,887,197  
    $7.98  
     7.4  
    $- 
  
    Exercisable as of March 31, 2025 
     2,027,405  
    $10.62  
     6.7  
    $- 
  
    Vested and expected to vest as of March 31, 2025 
     2,887,197  
    $7.98  
     7.4  
    $- 

The following table summarizes the total stock-based
compensation expense included in the unaudited consolidated statements of operations for the periods presented:

 SCHEDULE OF STOCK BASED COMPENSATION EXPENSES 

    2025  
    2024 

    For the three months  ended March 31, 

    2025  
    2024 
  
    Research and development 
    $69,662  
    $217,819 
  
    General and administrative 
     171,229  
     556,872 
  
    Total stock-based compensation expense 
    $240,891  
    $774,691 

As of March 31, 2025, total compensation cost not
yet recognized related to unvested stock options was approximately $0.8 million, which is expected to be recognized over a weighted-average
period of approximately 1.4 years.

The Company estimates the fair value of stock options
on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires estimates of highly
subjective assumptions, which affect the fair value of each stock option. No options were granted during the three months ended March 31,
2025.

The following table presents the exercise price of
outstanding stock options as of March 31, 2025:

 S